These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37731621)

  • 1. N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody.
    Zibat A; Zhang X; Dickmanns A; Stegmann KM; Dobbelstein AW; Alachram H; Soliwoda R; Salinas G; Groß U; Görlich D; Kschischo M; Wollnik B; Dobbelstein M
    iScience; 2023 Oct; 26(10):107786. PubMed ID: 37731621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
    Strizki JM; Gaspar JM; Howe JA; Hutchins B; Mohri H; Nair MS; Kinek KC; McKenna P; Goh SL; Murgolo N
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0095323. PubMed ID: 38047645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry.
    Urbanowicz K; Opielka M; Stegmann KM; Dickmanns A; Dobbelstein M; Peters GJ; Smoleński RT
    Nucleosides Nucleotides Nucleic Acids; 2024 May; ():1-9. PubMed ID: 38741480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.
    Stegmann KM; Dickmanns A; Heinen N; Blaurock C; Karrasch T; Breithaupt A; Klopfleisch R; Uhlig N; Eberlein V; Issmail L; Herrmann ST; Schreieck A; Peelen E; Kohlhof H; Sadeghi B; Riek A; Speakman JR; Groß U; Görlich D; Vitt D; Müller T; Grunwald T; Pfaender S; Balkema-Buschmann A; Dobbelstein M
    iScience; 2022 May; 25(5):104293. PubMed ID: 35492218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
    Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
    J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier.
    Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH
    EBioMedicine; 2023 Sep; 95():104748. PubMed ID: 37544201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
    Yip AJW; Low ZY; Chow VTK; Lal SK
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model.
    Kiy RT; Khoo SH; Chadwick AE
    Toxicol Res (Camb); 2024 Feb; 13(1):tfae012. PubMed ID: 38328743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
    Waters MD; Warren S; Hughes C; Lewis P; Zhang F
    Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
    Zhou S; Hill CS; Sarkar S; Tse LV; Woodburn BMD; Schinazi RF; Sheahan TP; Baric RS; Heise MT; Swanstrom R
    J Infect Dis; 2021 Aug; 224(3):415-419. PubMed ID: 33961695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
    Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
    J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
    Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
    J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat.
    Chang CH; Peng WY; Lee WH; Yang L; Lin TY; Yang MH; Tsai TH
    Commun Med (Lond); 2023 Oct; 3(1):150. PubMed ID: 37857815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
    Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
    Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants.
    Teli D; Balar P; Patel K; Sharma A; Chavda V; Vora L
    Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molnupiravir: Mechanism of action, clinical, and translational science.
    Maas BM; Strizki J; Miller RR; Kumar S; Brown M; Johnson MG; Cheng M; De Anda C; Rizk ML; Stone JA
    Clin Transl Sci; 2024 Feb; 17(2):e13732. PubMed ID: 38593352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing.
    Miranda JA; McKinzie PB; Dobrovolsky VN; Revollo JR
    Environ Mol Mutagen; 2022 Aug; 63(7):320-328. PubMed ID: 36181379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molnupiravir: an antiviral drug against COVID-19.
    Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
    Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.